MedPath

Duloxetine in patients with schizophrenia

Phase 2
Conditions
schizophrenia.
schizophrenia
Registration Number
IRCT201506201556N77
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

1-Diagnosis of Schizophrenia based on DSM-5 criteria; 2- Age between 18-60; 3-Chronic Schizophrenia- duration of the disorder more than 2 years; 4-Minimum score of 20 in negative sub score. 5-being stable on risperidone for the last 2 months Exclusion criteria:1-Any serious medical or neurological problem; 2- IQ less than 70; 3- Substance dependence during the last 6 months(except for nicotine and caffeine); 4- Score on HDRS less than 14 5-receiving ECT during the last 3 months ; 6-Acute or chronic systemic diseases; 7- History of neurosurgery; 8- History of head trauma

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath